Ones To Watch News
Refine Search
Biotechnology
San Diego-based Valora Therapeutics, a biotech that boasts of having a novel approach to immunotherapy, has announced the successful closing of a $30 million seed funding round. 21 November 2024
Biotechnology
Astellas Pharma has been hit by bad news from the US Food and Drug Administration, which will not currently approve the firm’s request to supplement the label for Izervay (avacincaptad pegol). 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Biotechnology
HCW Biologics has announced a worldwide licensing agreement with WY Biotech to develop and commercialize one of its preclinical immunotherapy candidates. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO). 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it released early-stage data on its FT819 in lupus. 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Biotechnology
Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study showing that abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, compared to rivaroxaban. 18 November 2024
Pharmaceutical
US clinical-stage biopharmaceutical company Boston Pharmaceuticals has announced positive results from a Phase II study evaluating the safety and efficacy of once-monthly efimosfermin alfa (formerly known as BOS-580), a long-acting FGF21 analogue, in participants with stage F2/F3 fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). 18 November 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
Danish pharma major Novo Nordisk and privately-held Californian firm Deep Apple Therapeutics have announced a research collaboration and exclusive worldwide license agreement. 11 June 2025
Biotechnology
US clinical-stage biotech Oncolytics Biotech today announced the appointment of Jared Kelly as chief executive (CEO) and a member of its board of directors. 11 June 2025
Pharmaceutical
USA-based Insmed Incorporated closed Tuesday’s trading up by more than a third. 11 June 2025
Biotechnology
Angelini Ventures has joined a syndicate of European life sciences investors to back Elkedonia, a French biotech developing a new class of neuroplastogens to treat depression and other neuropsychiatric conditions. 11 June 2025
Biotechnology
Boston, USA-based biotech Antares Therapeutics, launched yesterday with $177 million in Series A financing. 11 June 2025
Pharmaceutical
China-based biotech Innogen is making a strategic pivot toward international visibility following regulatory clearance of its first-in-class, ultra-long-acting GLP-1 receptor agonist for type 2 diabetes, alongside a move to go public on the Hong Kong Stock Exchange. 11 June 2025
Biotechnology
Spanish biotech SpliceBio has secured $135 million in series B financing to accelerate development of its experimental gene therapy, SB-007, for Stargardt disease and expand its broader pipeline of genetic medicines. 11 June 2025
Biotechnology
UK privately-held T-regulatory (Treg) cell therapies developer Quell Therapeutics today revealed that pharma major AstraZeneca has selected a lead Treg cell therapy candidate to progress from the inflammatory bowel disease (IBD) program. 10 June 2025
Pharmaceutical
UK-based microbiome company Microbiotica has appointed Robert Tansley its chief medical officer (CMO). 10 June 2025
Pharmaceutical
New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, closed Monday’s trading nearly 11% higher. 10 June 2025
Biosimilars
Specialty immunotherapy company Tevogen Bio Holdings has announced the execution of a lease agreement to expand its corporate headquarters in Warren, New Jersey, more than doubling its footprint. 10 June 2025
Biotechnology
Swiss pharma company Idorsia today announced the appointment of Dr Srishti Gupta as chief executive (CEO), effective July 1, 2025. 10 June 2025
Biotechnology
Dutch late-stage biotech NewAmsterdam Pharma late yesterday announced positive top-line data from prespecified Alzheimer’s disease (AD) biomarker analyses in the Phase III BROADWAY clinical trial (NCT05142722). The firm’s US-traded shares were up 4.1% at $20.99 in pre-market activity this morning. 10 June 2025
Biotechnology
Shares of USA-based Elevation Oncology leapt more than 20% to $0.38, on the news that it has accepted a takeover bid from Concentra Biosciences, a vehicle controlled by hedge fund Tang Capital Partners, an investment firm focused on buying struggling biotechs and shutting them down. 10 June 2025
Biotechnology
US ophthalmic gene therapy company Beacon Therapeutics, which is focused on restoring the vision of patients with blinding retinal diseases, has appointed Daniel Chung as chief medical officer (CMO). 9 June 2025
Biotechnology
France-based SparingVision, a genomic medicine company focused on the treatment of retinal disease, has announced the appointment of Kalliopi ‘Kali’ Stasi, as chief medical officer, effective immediately. 9 June 2025
Biotechnology
Shares of Avidity Biosciences were up almost 5% at $38.00 pre-market today, as it announced the accelerated approval regulatory pathway in the USA is open for delpacibart braxlosiran (del-brax) in the treatment of facioscapulohumeral muscular dystrophy (FSHD). 9 June 2025
Pharmaceutical
George Medicines, a late-stage UK-based biopharmaceutical company focused on addressing unmet needs in cardiometabolic disease, revealed a regulatory approval that it says could reshape hypertension treatment in the USA. 9 June 2025
Pharmaceutical
Canada-based Knight Therapeutics and the US subsidiary of Japan’s Sumitomo Pharma have entered into exclusive license and supply agreements to commercialize certain products. 9 June 2025
Biotechnology
Texas-based ImmunoPrecise Antibodies, a leader in AI-driven biotherapeutics, closed 22% higher Thursday. 6 June 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze